Guard Therapeutics: Phase IIb study POINTER ends in failure - Redeye
Bildkälla: Stockfoto

Guard Therapeutics: Phase IIb study POINTER ends in failure - Redeye

Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not meet its endpoints in its phase IIb study POINTER. We anticipate a share price decline of 80-90% today.

Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not meet its endpoints in its phase IIb study POINTER. We anticipate a share price decline of 80-90% today.
Börsvärldens nyhetsbrev